Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (NCT05985655) | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 2023-07-06 |
Track Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC) automatically
Every clearance here is in the API, with alerts when new ones post.